BioCryst Pharmaceuticals Enters Material Definitive Agreement
Ticker: BCRX · Form: 8-K · Filed: Jun 30, 2025 · CIK: 882796
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: BCRX
TL;DR
BioCryst just signed a big deal, details TBD.
AI Summary
On June 27, 2025, BioCryst Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Durham, North Carolina, filed this 8-K report to disclose this event. No specific details of the agreement or financial implications were provided in this filing excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for BioCryst Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant risks and rewards, but the lack of detail prevents a precise assessment.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Address of Principal Executive Offices
FAQ
What type of material definitive agreement did BioCryst Pharmaceuticals, Inc. enter into?
The provided excerpt does not specify the nature of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2025.
Where are BioCryst Pharmaceuticals, Inc.'s principal executive offices located?
BioCryst Pharmaceuticals, Inc.'s principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina.
What is BioCryst Pharmaceuticals, Inc.'s fiscal year end?
BioCryst Pharmaceuticals, Inc.'s fiscal year ends on December 31.
What is the Commission File Number for BioCryst Pharmaceuticals, Inc.?
The Commission File Number for BioCryst Pharmaceuticals, Inc. is 000-23186.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).